CO2018007440A2 - Análogos del egf(a) con sustituyentes de ácidos grasos - Google Patents

Análogos del egf(a) con sustituyentes de ácidos grasos

Info

Publication number
CO2018007440A2
CO2018007440A2 CONC2018/0007440A CO2018007440A CO2018007440A2 CO 2018007440 A2 CO2018007440 A2 CO 2018007440A2 CO 2018007440 A CO2018007440 A CO 2018007440A CO 2018007440 A2 CO2018007440 A2 CO 2018007440A2
Authority
CO
Colombia
Prior art keywords
egf
fatty acid
analogues
compounds
acid substituents
Prior art date
Application number
CONC2018/0007440A
Other languages
English (en)
Spanish (es)
Inventor
Jianhe Chen
Jesper F Lau
János Tibor Kodra
Birgit Wieczorek
Lars Linderoth
Henning Thøgersen
Salka Elbøl Rasmussen
Patrick William Garibay
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CO2018007440A2 publication Critical patent/CO2018007440A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CONC2018/0007440A 2016-01-13 2018-07-16 Análogos del egf(a) con sustituyentes de ácidos grasos CO2018007440A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2016070791 2016-01-13
CN2016076580 2016-03-17
EP16195965 2016-10-27
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Publications (1)

Publication Number Publication Date
CO2018007440A2 true CO2018007440A2 (es) 2018-09-28

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007440A CO2018007440A2 (es) 2016-01-13 2018-07-16 Análogos del egf(a) con sustituyentes de ácidos grasos

Country Status (26)

Country Link
US (2) US10822385B2 (enExample)
EP (1) EP3402811B1 (enExample)
JP (2) JP6797926B2 (enExample)
KR (1) KR102417487B1 (enExample)
CN (1) CN108473550B (enExample)
AU (1) AU2017207862B2 (enExample)
BR (1) BR112018013820A2 (enExample)
CA (1) CA3010756A1 (enExample)
CL (1) CL2018001868A1 (enExample)
CO (1) CO2018007440A2 (enExample)
DK (1) DK3402811T3 (enExample)
ES (1) ES2916998T3 (enExample)
HR (1) HRP20220720T1 (enExample)
HU (1) HUE058647T2 (enExample)
IL (1) IL260043A (enExample)
LT (1) LT3402811T (enExample)
MX (1) MX2018008681A (enExample)
MY (1) MY195199A (enExample)
PE (1) PE20181376A1 (enExample)
PH (1) PH12018501502A1 (enExample)
PL (1) PL3402811T3 (enExample)
RS (1) RS63298B1 (enExample)
RU (1) RU2747877C2 (enExample)
SA (1) SA518391996B1 (enExample)
SI (1) SI3402811T1 (enExample)
WO (1) WO2017121850A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3402785T (lt) 2016-01-13 2020-04-10 Grünenthal GmbH 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
HUE051642T2 (hu) 2016-01-13 2021-03-01 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4,5]-dekán származékok
PL3402784T3 (pl) 2016-01-13 2020-09-21 Grünenthal GmbH Pochodne 3-((hetero-)arylo)-alkilo-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekanu
BR112018013820A2 (pt) 2016-01-13 2018-12-11 Novo Nordisk A/S análogos de egf(a) com substituintes de ácido graxo
EA202190281A1 (ru) 2016-01-13 2021-09-01 Грюненталь Гмбх Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана
AU2018303625A1 (en) 2017-07-19 2020-02-06 Novo Nordisk A/S Bifunctional compounds
CN111164098A (zh) * 2017-07-19 2020-05-15 诺沃挪第克公司 Egf(a)类似物、其制品、制剂和用途
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University Fatty acid modified human epidermal growth factor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
WO2020070276A1 (en) 2018-10-05 2020-04-09 Novo Nordisk A/S Bifunctional compounds comprising insulin peptides and egf(a) peptides
CA3131997A1 (en) 2019-03-22 2020-10-01 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
KR20220046565A (ko) 2019-08-07 2022-04-14 노보 노르디스크 에이/에스 Egf(a) 유도체 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
EP4054520A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP4403233A3 (en) 2021-07-02 2025-02-12 3M Innovative Properties Company Aerial lift interlocked with fall-protection safety apparatus
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616551A1 (en) 2005-07-29 2007-02-15 Amprotein Corporation Chimeric therapeutic agents
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2009131740A2 (en) * 2008-04-23 2009-10-29 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
US8939592B2 (en) 2010-08-02 2015-01-27 Nec Corporation Polarizer and light-emitting device
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
CN103370075A (zh) 2011-02-15 2013-10-23 诺沃—诺迪斯克有限公司 长效il-1受体拮抗剂
BR112013032667A2 (pt) * 2011-06-20 2017-12-12 Genentech Inc polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra
CA2849673A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JP2015502971A (ja) * 2011-12-21 2015-01-29 ノヴォ ノルディスク アー／エス Ｎ末端修飾インスリン誘導体
CN107739409A (zh) 2012-05-18 2018-02-27 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
TW201420606A (zh) 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
EP2892919A1 (en) 2012-09-07 2015-07-15 Sanofi Fusion proteins for treating a metabolic syndrome
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2015127273A1 (en) 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9~glp-1 fusions and methods for use
JP2017525656A (ja) * 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
US20180207223A1 (en) * 2015-03-19 2018-07-26 Institut De Cardiologie De Montreal Pcsk9 inhibitory polypolypeptides and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
BR112018013820A2 (pt) 2016-01-13 2018-12-11 Novo Nordisk A/S análogos de egf(a) com substituintes de ácido graxo
AU2018303625A1 (en) 2017-07-19 2020-02-06 Novo Nordisk A/S Bifunctional compounds
CN111164098A (zh) 2017-07-19 2020-05-15 诺沃挪第克公司 Egf(a)类似物、其制品、制剂和用途

Also Published As

Publication number Publication date
EP3402811A1 (en) 2018-11-21
KR102417487B1 (ko) 2022-07-06
KR20180100177A (ko) 2018-09-07
EP3402811B1 (en) 2022-03-30
IL260043A (en) 2018-07-31
CA3010756A1 (en) 2017-07-20
HUE058647T2 (hu) 2022-09-28
PH12018501502A1 (en) 2019-03-25
JP6797926B2 (ja) 2020-12-09
US20200407409A1 (en) 2020-12-31
CN108473550A (zh) 2018-08-31
RS63298B1 (sr) 2022-07-29
US10822385B2 (en) 2020-11-03
SA518391996B1 (ar) 2021-07-14
RU2018127882A (ru) 2020-02-13
PE20181376A1 (es) 2018-09-05
PL3402811T3 (pl) 2022-07-11
AU2017207862B2 (en) 2020-12-17
CL2018001868A1 (es) 2018-08-31
RU2747877C2 (ru) 2021-05-17
SI3402811T1 (sl) 2022-06-30
DK3402811T3 (da) 2022-06-13
WO2017121850A1 (en) 2017-07-20
CN108473550B (zh) 2022-11-22
JP2021035989A (ja) 2021-03-04
ES2916998T3 (es) 2022-07-06
RU2018127882A3 (enExample) 2020-06-19
US20190016768A1 (en) 2019-01-17
HRP20220720T1 (hr) 2022-09-30
BR112018013820A2 (pt) 2018-12-11
LT3402811T (lt) 2022-06-10
MY195199A (en) 2023-01-11
JP2019505521A (ja) 2019-02-28
MX2018008681A (es) 2018-09-17
AU2017207862A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
CO2018007440A2 (es) Análogos del egf(a) con sustituyentes de ácidos grasos
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2017002650A1 (es) Compuestos novedosos
CO2019008684A2 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cancer
ECSP19035077A (es) Inhibidores de magl
DOP2019000121A (es) Inhibidores de magl
MX380829B (es) Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
PE20160167A1 (es) Composiciones y metodos para alterar la senalizacion del segundo mensajero
EA201890592A1 (ru) Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
MX2019001718A (es) Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento.
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
CR20170591A (es) Benzamidas sustituidas y métodos para utilizarlas
CL2020001687A1 (es) Nuevos compuestos inhibidores del blanco mecanístico de rapamicina (mtor).
CO2018007663A2 (es) Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP15009391A (es) siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"